Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Hematology/Oncology Clinics of North America

• Publication date

  2008-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.hoc.2008.08.003PMID 19010268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of Chemosensitivity Using Multigene Analysis in Head and Neck Squamous Cell Carcinoma

  2008cited by this paper
• Should there be more molecular staging of head and neck cancer to improve the choice of treatments and thereby improve survival?

  2008cited by this paper
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

  2008cited by this paper
• TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

  2007cited by this paper
• Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

  2007cited by this paper
• Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck.

  2007cited by this paper
• Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

  2007cited by this paper
• Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

  2007cited by this paper
• Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.

  2007cited by this paper
• Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC)

  2007cited by this paper
• Retrospective analysis of the addition of cetuximab to induction chemotherapy (IC) with docetaxel, cisplatin, and 5-fluorouracil (TPF-C) for locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC)

  2007cited by this paper
• Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation.

  2007cited by this paper
• Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

  2007cited by this paper
• Impact of vascular endothelial growth factor release on radiation resistance.

  2007cited by this paper
• The changing face of p53 in head and neck cancer.

  2007cited by this paper
• Phase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results

  2007cited by this paper
• Gefitinib plus concomitant boost accelerated radiation (AFX-CB) and concurrent weekly cisplatin for locally advanced unresectable squamous cell head and neck carcinomas (SCCHN): A phase II study

  2007cited by this paper
• Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303)

  2007cited by this paper
• Pilot phase I study of gefitinib (GEF) in combination with paclitaxel (PAC) and radiation therapy (RT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and effects on epidermal growth factor receptor (EGFR) signaling pathway

  2007cited by this paper
• Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN)

  2007cited by this paper
• Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma

  2007cited by this paper
• Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

  2007cited by this paper
• Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.

  2007cited by this paper
• Molecular markers of head and neck squamous cell carcinoma: Promising signs in need of prospective evaluation

  2006cited by this paper
• Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network.

  2006cited by this paper
• p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck

  2006cited by this paper
• A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

  2006cited by this paper
• Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN).

  2006cited by this paper
• A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC).

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

  2006cited by this paper
• Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.

  2006cited by this paper
• Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer.

  2006cited by this paper
• Molecular biology of squamous cell carcinoma of the head and neck

  2006cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

  2005cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

  2005cited by this paper
• The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.

  2005cited by this paper
• Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR

  2005cited by this paper
• Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Accelerated hyperfractionated chemoradiation (C-HART) plus 5-FU/MMC is superior to HART for inoperable locally advanced head and neck cancer. Final results of the German ARO 95-06 Multicentre Trial.

  2004cited by this paper
• Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

  2004cited by this paper
• Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines

  2004cited by this paper
• Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy.

  2004cited by this paper
• Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Role of an Anti-epidermal Growth Factor Receptor in Treating Cancer

  2004cited by this paper
• Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

  2004cited by this paper
• Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice

  2003cited by this paper
• Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma

  2002cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer.

  2002cited by this paper
• The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy.

  2001cited by this paper
• Antisense Cyclin D1 Enhances Sensitivity of Head and Neck Cancer Cells to Cisplatin

  2001cited by this paper
• A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

  2000cited by this paper
• p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.

  2000cited by this paper
• Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx Carcinoma.

  1999cited by this paper
• p53 expression in locally advanced pharyngeal squamous cell carcinoma.

  1999cited by this paper
• A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003

  1999cited by this paper
• Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

  1999cited by this paper
• Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck.

  1997cited by this paper
• Head and neck carcinoma--stage at presentation.

  1994cited by this paper
• ras Mutations and expression in head and neck squamous cell carcinomas

  1994cited by this paper
• Prevalence of RAS oncogene mutation in head and neck carcinomas.

  1992cited by this paper

• Utility of ultrasound examination in the diagnosis of laryngeal and hypopharyngeal cancers

  2019cites this paper
• Immunotherapy for Head and Neck Squamous Cell Carcinoma.

  2015cites this paper
• Opportunities and Challenges for the Future of Personalized Oral Healthcare

  2015cites this paper
• BASIC SCIENCE REVIEW

  2010cites this paper
• Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity.

  2010cites this paper
• Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials

  2009cites this paper